Mr. Hunt is a Senior Principal in CBPartners’ Value Access & Pricing practice. His experience as a global life sciences strategy consultant spans all stages of product development and a wide range of therapeutic areas, including oncology, inflammatory conditions, cardiovascular diseases, respiratory illnesses, and orphan diseases.
In his time at CBPartners, Mr. Hunt’s engagement work has targeted a variety of commercial business issues related to pricing, access, and value with a focus in pricing and market access strategy in the U.S. and other global developed markets. Mr. Hunt is devoted to delivering innovative and impactful commercial strategy recommendations to biopharmaceutical manufacturers working to navigate the evolving global payer marketplace.
Prior to joining CBPartners, Mr. Hunt worked in the strategy consulting division of Leerink Partners. Mr. Hunt holds a BS in Biomedical Engineering from Johns Hopkins University.
THE COVID-19 Pandemic: Pricing and Access Outlook for Future Innovative Drugs in Europe
6 April 2020
The Cancer Drugs Fund: Paving the way for earlier and more sustainable access to promising new drugs
19 November 2019
NICE Invites Pharma to Start the Conversation Early, with a View Towards Shifting Away from ‘No’ as the Starting Point
24 July 2019
Strategic Patient Advocacy vs. Evidence Package: The “Rare” Challenge for Orphan Drug Manufacturers
28 February 2017
We’re Going to Need a Bigger Boat: How UnitedHealth’s $12.8B Acquisition of Catamaran Creates a Unique Force in the Ongoing PBM Battle Against Rising Specialty Drug Costs
20 April 2015
THOUGHT PIECE: Evolution of the PA: Where We Are and Where We Are Heading
3 April 2015